Regeneron Pharmaceuticals Inc

Quantli Newsdesk

· 3 months ago

Regeneron's experimental cancer treatment fianlimab, combined with its approved drug Libtayo (cemiplimab), failed to show statistically significant improvement in progression-free survival versus Merck's Keytruda in a late-stage melanoma trial. The setback adds pressure on Regeneron's pipeline following recent drug failures and regulatory delays, prompting at least 10 brokerages to cut their price targets.

10-K

Quantli Newsdesk

· 4 months ago

Regeneron reported $14.3 billion in 2025 revenues, up modestly from 2024, as surging Dupixent collaboration profits offset a 42% decline in U.S. EYLEA sales driven by biosimilar competition and patient migration to EYLEA HD.